7/5/2013

Blaze Biosciences, a Seattle-based firm, has pulled in about $8.1 million of a hoped-for $15 million Series B funding round. The money will go toward development of the company's Tumor Paint technology, which aids surgeons in targeting cancerous tissue by distinguishing healthy tissue from solid tumor tissue.

Related Summaries